glp-1/gip agonists Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes Schematic illustration of monoagonists, dual

Bridgewater, NJ: Sanofi-aventis U.S., LLC.;2019

Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme

This dual action makes Mounjaro potentially more effective for blood sugar control compared to Ozempic

Glucagon-like peptide 1 receptor agonists potential game changers in the treatment of glaucoma

[Preprint] [DOI] [Google Scholar] 56.GLP-1 drug liraglutide may protect against dementia

Pediatric and Adolescent Obesity Treatment: Since FDA approval in 2022, GLP-1 receptor agonists have been prescribed for individuals aged 12 years and older with obesity (BMI 95th percentile)